<DOC>
	<DOCNO>NCT02219516</DOCNO>
	<brief_summary>This Phase 1 , single-dose , open-label , pharmacokinetic ( PK ) pharmacodynamic ( PD ) study RDEA3170 adult male subject mild , moderate , severe renal impairment .</brief_summary>
	<brief_title>Mild , Moderate Severe Renal Impairment Study</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject body weight ≥ 50 kg ( 110 lb . ) body mass index ≥ 18 ≤ 40 kg/m2 . Subject renal impairment , determine Screening , creatinine clearance calculate CockcroftGault formula 60 &lt; 90 mL/min ( mild impairment ) , 30 &lt; 60 mL/min ( moderate impairment ) , 15 &lt; 30 mL/min ( severe impairment ) , match control subject ( age body mass index ) creatinine clearance ≥ 90 mL/min . Subject Screening serum urate level ≥ 4.5 mg/dL ≤ 10 mg/dL Subject history clinical manifestation significant metabolic , hematological , pulmonary , cardiovascular , gastrointestinal , neurologic , hepatic , renal , urological , psychiatric disorder . Subject history suspicion kidney stone . Subject history asthma . Subject undergone major surgery within 3 month prior Day 1 . Subject donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1 give plasma donation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>